Functionality of Albumin in the Context of Hemodialysis

Recruiting now · Not applicable

Conditions studied: Albumin, Dialysis, Redox State, Uremic; Toxemia

In brief

Hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. At the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chronically increased level of inflammation and usually incomplete removal of uraemic toxins. Both of these are closely linked with the functional properties of albumin. The aim of this study is to investigate the effects of various parameters of dialysis, in particular dialyzer properties and dialysis mode on the functional properties of albumin and to what extent these parameters can be used therapeutically, to improve the treatment quality of hemodialysis treatment in the long term by modifying albumin functional properties. Our own preliminary work in this field and the current state of research indicate that, for example, the use of high-flux dialyzers can contribute to a reduction of the oxidative stress level. It also appears possible that treatment mode (haemodiafiltration instead of haemodialysis) may also have an effect on the binding and detoxification efficiency of albumin and thus on the removal of uraemic toxins. Previous results have mostly been collected in observational studies. As a proof-of-concept study, this study will further investigate the concrete therapeutic applicability in an interventional study design.

Key facts

Study ID

NCT06561191

Run by

Universität Duisburg-Essen

People needed

50

Starts

2024-08-01

Expected to finish

2025-12-01

Last updated by the study team

2024-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older at least 3 month of hemodialysis treatment (3x/week) with constant dialysis treatment regimen

You may not qualify if…

• Age ≤ 18 years
• Less than three months of regular (3x/week) hemodialysis treatments or less than 3 treatments/week
• Acute or chronic liver disease (Child stage A or higher or fulfillment of the of the Kings College criteria)
• Infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion
• Acute or severe chronic infections
• Acute tumor disease

Where it is running

• University Hospital Essen — Essen, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.